OVID · Ovid Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| TAKEDA PHARMACEUTICAL CO LTD 10% Owner | ▼ Sell | Other | 7,000,000 Shares held | 12/8/2025 | View profile |
| Jeremy M. Levin CEO | ▲ Buy | Option Exercise | 3,735,048 Shares held | 3/23/2026 | View profile |
| Stelios Papadopoulos Director | ▲ Buy | Grant | 217,578 Shares held | 4/7/2026 | View profile |
| Jeffrey A. Rona CBFO | ▲ Buy | Grant | 156,313 Shares held | 2/26/2026 | View profile |
| Charles Ross Carter Chief Financial Officer | ▲ Buy | Grant | 94,375 Shares held | 7/6/2026 | View profile |
| Margaret A. Alexander President and COO | ▼ Sell | Open Market | 61,750 Shares held | 2/23/2026 | View profile |
| Jason Tardio Chief Operating Officer | ▲ Buy | Grant | 28,125 Shares held | 2/22/2024 | View profile |
| Thomas Michael Perone General Counsel, Secretary | ▲ Buy | Grant | 28,125 Shares held | 2/22/2024 | View profile |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | ▲ Buy | Grant | 17,578 Shares held | 4/7/2026 | View profile |
| Bart Friedman | ▲ Buy | Grant | 8,789 Shares held | 4/7/2026 | View profile |
Transaction History
| Charles Ross Carter | ▲ Buy | Grant | 50,000 | $0 | 7/6/2026 |
| Kevin Joseph Fitzgerald | ▲ Buy | Grant | 17,578 | $45K | 4/7/2026 |
| Stelios Papadopoulos | ▲ Buy | Grant | 17,578 | $45K | 4/7/2026 |
| Bart Friedman | ▲ Buy | Grant | 8,789 | $22K | 4/7/2026 |
| Jeremy M. Levin | ▲ Buy | Option Exercise | 47,333 | $66K | 3/23/2026 |
| Jeffrey A. Rona | ▲ Buy | Grant | 68,125 | $0 | 2/26/2026 |
| Margaret A. Alexander | ▼ Sell | Open Market | 11,656 | $17K | 2/23/2026 |
| Jeffrey A. Rona | ▼ Sell | Open Market | 8,541 | $12K | 2/23/2026 |
| Jeremy M. Levin | ▼ Sell | Other | 71,000 | — | 12/15/2025 |
| TAKEDA PHARMACEUTICAL CO LTD | ▼ Sell | Other | 1,250,000 | $0 | 12/8/2025 |
| Margaret A. Alexander | ▼ Sell | Open Market | 5,279 | $3K | 2/26/2025 |
| Jeffrey A. Rona | ▼ Sell | Open Market | 3,902 | $2K | 2/26/2025 |
| Margaret A. Alexander | ▲ Buy | Grant | 43,750 | $0 | 2/20/2025 |
| Jeffrey A. Rona | ▲ Buy | Grant | 43,750 | $0 | 2/20/2025 |
| Margaret A. Alexander | ▲ Buy | Open Market | 6,810 | $5K | 1/27/2025 |
| Jeremy M. Levin | ▲ Buy | Open Market | 18,248 | $50K | 3/18/2024 |
| Jason Tardio | ▲ Buy | Grant | 28,125 | $0 | 2/22/2024 |
| Jeffrey A. Rona | ▲ Buy | Grant | 28,125 | $0 | 2/22/2024 |
| Thomas Michael Perone | ▲ Buy | Grant | 28,125 | $0 | 2/22/2024 |
| Jeremy M. Levin | ▼ Sell | Gift | 573,275 | $0 | 12/4/2023 |
| Jeremy M. Levin | ▼ Sell | Gift | 573,275 | $0 | 12/4/2023 |
| Jason Tardio | ▼ Sell | Open Market | 17,344 | $37K | 9/12/2022 |
| TAKEDA PHARMACEUTICAL CO LTD | ▼ Sell | Other | 5,750,000 | $0 | 7/1/2022 |
| TAKEDA PHARMACEUTICAL CO LTD | ▼ Sell | Other | 5,750,000 | $0 | 7/1/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Ovid Therapeutics shares decline in pre-market session
Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.
Ovid Therapeutics shares decline in pre-market session. Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.